End points in trials of treatments for skin infections

JAMA

Volumn 309, Issue 20, 2013, Pages 2091-2092

  Spellberg, Brad ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; TEDIZOLID;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ANTIBIOTIC THERAPY; BACTERIAL SKIN DISEASE; CLINICAL TRIAL (TOPIC); DRUG TREATMENT FAILURE; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 84877980271     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.4541     Document Type: Letter

References (2)

1. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559-569.
2. European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003417.pdf. Accessed February 17, 2013.